ACOR(Delisted)
Acorda Therapeutics·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ACOR
Acorda Therapeutics, Inc.
A biopharmaceutical company that developing therapies for neurological disorders
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York 10965
--
Acorda Therapeutics, Inc., was incorporated in Delaware in 1995. Acorda Medical is a commercial-development-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that help improve neurological function in multiple sclerosis, spinal cord injury and other central nervous system diseases. The company's goal is to help patients have a better future while building a leading neuroscience company with a portfolio of innovative products.
Company Financials
EPS
ACOR has released its 2023 Q3 earnings. EPS was reported at -7.16, versus the expected 0, missing expectations. The chart below visualizes how ACOR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ACOR has released its 2023 Q4 earnings report, with revenue of 37.98M, reflecting a YoY change of 20.70%, and net profit of -217.76M, showing a YoY change of -1237.61%. The Sankey diagram below clearly presents ACOR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
